Enzon Pharmaceuticals has announced that the European Commission has approved its Cimzia for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
Cimzia (certolizumab pegol) is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB.
The company said that Cimzia is one of several products which utilises its PEGylation technology, including Oncaspar, Adagen, Pegintron, Macugen and Pegasys.
The company’s drug development programs utilises several approaches including its PEGylation technology platform and the Locked Nucleic Acid (LNA) technology. Enzon’s PEGylation technology is used to develop two of its products, Oncaspar and Adagen. The company also engages in contract manufacturing for several pharmaceutical companies to broaden its revenue base.
Jeffrey Buchalter, president and CEO of Enzon, said: “Our PEGylation technology continues to enable very important therapeutics like Cimzia, benefiting patients with a wide variety of diseases.”
Enzon Pharmaceuticals is a biopharmaceutical company dedicated to developing, manufacturing and commercializing medicines for patients with cancer and other life-threatening conditions. The company has a portfolio of four marketed products – Oncaspar, DepoCyt, Abelcet and Adagen.